Comment from Innovative Medicines Initiative, Big Picture project

Summary: The IMI Big Picture consortium welcomes the draft guidance as a necessary first step for addressing AI in the regulatory space for drug and biological products. They provide specific technical feedback and requests for clarification regarding risk classification, model parameters, explainability, and the scope of the guidance.